Chemo-radionuclide therapy halts neuroendocrine cancer

Combined chemo and radionuclide therapy with radiosensitizing drugs slows or stops disease progression and leads to better patient survival

2014-06-09

(Press-News.org) St. Louis, Mo. (June 9, 2014) – Advanced cancer of the neuroendocrine system can lead to dismal prognoses, but a novel therapy is packing a punch by uniting powerful radionuclide treatment and chemotherapy drugs, revealed researchers at the Society of Nuclear Medicine and Molecular Imaging's 2014 Annual Meeting.

The research findings show that the experimental therapy led to stabilization or regression of patients' cancer in about 70 percent of cases a year after completion of the treatment, now called peptide receptor chemo-radionuclide therapy (PRCRT). The therapy is just catching on across Europe and Australia and now in U.S. clinical trials.

"Results of this study suggest that PRCRT is a highly effective treatment option for patients with progressive NETs with high somatostatin receptor expression," explained Grace Kong, MBBS, principal investigator for this study conducted at the Centre for Cancer Imaging, Peter MacCallum Cancer Centre in Melbourne, Australia.

Neuroendocrine tumors (NETs) are those that develop within a multiplicity of organs throughout the body that have nerve cells and interact with the endocrine system through chemical signaling made possible with various hormones. These tumors usually develop along the intestines and lungs, but they can also be found in the pancreas and many other sites, although rarely. For this study, researchers observed patients who had undergone at least three courses of treatment with Lutetium-177 DOTA-Octreotate, which is prescribed for inoperable patients with NETs expressing somatostatin hormone receptors. This study included a high proportion of grade two disease, which is more aggressive and associated with adverse prognosis. Researchers added a radio-sensitizing chemotherapy for 63 out of the 68 patients in the study.

All of these steps together produced encouraging responses in a majority of subjects, with 72 percent survival at two years. More than half of patients were still alive past the five-year mark after therapy. "The high objective response and long median survival even in patients with more aggressive tumor biology warrant further studies comparing it with other targeted therapies recently approved, despite much lower response rates," Kong added.

INFORMATION: Scientific Paper 256: Grace Kong, Mick Thompson, Marnie Collins, Alan Herschtal, Michael Hofman, Val Johnston, Peter Eu, Michael Michael, Rodney Hicks, Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia, "Response, predictors and long-term outcome of peptide receptor chemoradionuclide therapy (PRCRT) for neuroendocrine tumours," SNMMI's 61th Annual Meeting, June 7, 2014, St. Louis, Missouri.

About the Society of Nuclear Medicine and Molecular Imaging

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is an international scientific and medical organization dedicated to raising public awareness about nuclear medicine and molecular imaging, a vital element of today's medical practice that adds an additional dimension to diagnosis, changing the way common and devastating diseases are understood and treated and helping provide patients with the best health care possible.

SNMMI's more than 18,000 members set the standard for molecular imaging and nuclear medicine practice by creating guidelines, sharing information through journals and meetings and leading advocacy on key issues that affect molecular imaging and therapy research and practice. For more information, visit http://www.snmmi.org.

ELSE PRESS RELEASES FROM THIS DATE:

Opti-SPECT/PET/CT: 5 different imaging systems now combined

2014-06-09

St. Louis, Mo. (June 9, 2014) – Taking their pick, biomedical researchers can now conduct five different imaging studies in one scan with a state-of-the-art preclinical molecular imaging system that scientists unveiled during the Society of Nuclear Medicine and Molecular Imaging's 2014 Annual Meeting. The imaging device allows single photon emission tomography (SPECT), positron emission tomography (PET), X-ray computed tomography, fluorescence and bioluminescence imaging—powerful imaging techniques that provide different information about anatomy and physiological processes ...

Radioluminescence tells the story of single cells

2014-06-09

St. Louis, Mo. (June 9, 2014) – With a new molecular imaging system powerful enough to peer down to 20-micrometer resolution, researchers can now use radioluminescence to examine the characteristics of single, unconnected cells. The result is a fascinating picture of diversity among cells previously assumed to behave the same, revealed researchers at the Society of Nuclear Medicine and Molecular Imaging's 2014 Annual Meeting. A resolution of 20 micrometers or microns—about a quarter of the diameter of a single human hair—is made possible with an imaging technique that ...

Enzyme-inhibition could revolutionize molecular imaging

2014-06-09

St. Louis, Mo. (June 9, 2014) – The prominent role a single enzyme plays in cancer imaging has eluded researchers for years, but not anymore. This discovery could pave new avenues in nuclear medicine. The enzyme, called neutral endopeptidase (NEP), has a way of breaking down most radiopeptide imaging agents in the body. Researchers have developed an elegant new concept that improves molecular imaging, according to study results presented during the Society of Nuclear Medicine and Molecular Imaging's 2014 Annual Meeting. The sneaky enzyme has evaded studies with peptide ...

Molecular imaging gets to the root of rheumatoid arthritis

2014-06-09

St. Louis, Mo. (June 9, 2014) – Rheumatoid arthritis causes chronic pain for almost half of adults by the time they retire, but a new molecular imaging technique can visualize inflammation in the joints, giving doctors a clear read on chronic pain and possible joint destruction, say researchers at the Society of Nuclear Medicine and Molecular Imaging's 2014 Annual Meeting. In order to image arthritis inside the joints, researchers used multiple molecular imaging systems, positron emission tomography (PET) and single photon emission tomography (SPECT), both of which image ...

Depression in the elderly linked to Alzheimer's risk

2014-06-09

St. Louis, Mo. (June 9, 2014) – Many people develop depression in the latest stages of life, but until now doctors had no idea that it could point to a build up of a naturally occurring protein in the brain called beta-amyloid, a hallmark of Alzheimer's disease. In fact, late-life depression could become a major risk factor for developing Alzheimer's faster than others, according to research unveiled at the Society of Nuclear Medicine and Molecular Imaging's 2014 Annual Meeting. Alzheimer's disease is a currently incurable neurodegenerative disease with marked protein ...

REM sleep disturbance signals future neurodegenerative disease

2014-06-09

St. Louis, Mo. (June 9, 2014) – How many millions of people suffer from sleep disturbance? One sleep disorder in particular, called REM behavior disorder, could be a sign of impending neurodegenerative disease, including Parkinson's and dementia, say scientists presenting their research at the Society of Nuclear Medicine and Molecular Imaging's 2014 Annual Meeting. Researchers are not sure why spontaneous and unexplained disturbance in REM sleep should lead to a neurodegenerative disease like Parkinson's, but new longitudinal imaging data show a clear correlation between ...

A few circulating cancer cells could cue risk of metastases

2014-06-09

St. Louis, Mo. (June 9, 2014) – A simple noninvasive blood test matched with state-of-the-art molecular imaging of individual cells could help oncologists understand their patients' chances of survival, say researchers at the Society of Nuclear Medicine and Molecular Imaging's 2014 Annual Meeting. Metastasis accounts for an estimated 90 percent of cancer deaths. For decades, researchers tried to develop a way to gauge a cancer's risk of metastasizing from a blood sample—the long-sought-after liquid biopsy. Today there are numerous methods available to isolate lone cells. ...

Molecular imaging finds novel way to knock down breast cancer

2014-06-09

St. Louis, Mo. (June 9, 2014) – For years researchers have been developing molecular imaging techniques that visualize hormonally active breast cancer cells—specifically those testing positive for human epidermal growth factor receptor 2 (HER2). A recent innovation in breast cancer biomarkers seeks the HER3 receptor instead, which could mean more comprehensive breast cancer imaging and potential treatments, say experts presenting data during the Society of Nuclear Medicine and Molecular Imaging's 2014 Annual Meeting. Breast cancer is one of the most prevalent forms of ...

PSMA-based imaging traces even treatment-resistant prostate cancer

2014-06-09

St. Louis, Mo. (June 9, 2014) – Anti-androgen hormonal therapy, also called chemical castration, can be an important defense against further disease progression for patients with prostate cancer that has traveled and grown in other areas, or metastasized—but some cases simply do not respond to this treatment. A groundbreaking molecular imaging agent has been developed to help clinicians find as much cancer as possible, whether it is responding favorably or not, in an effort to improve clinical decision making for these patients, say researchers at the Society of Nuclear ...

Molecular breast imaging protocol unmasks more cancer

2014-06-09

St. Louis, Mo. (June 9, 2014) – Patients with advanced breast cancer that may have spread to their lymph nodes could benefit from a more robust dose of a molecular imaging agent called Tc-99m filtered sulfur colloid when undergoing lymphoscintigraphy, a functional imaging technique that scouts new cancer as it begins to metastasize. Best results also indicate that imaging could be improved by injecting the agent the day prior to surgical resection, according to research unveiled at the Society of Nuclear Medicine and Molecular Imaging's 2014 Annual Meeting. "The innovative ...